{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T08:18:15Z","timestamp":1787905095969,"version":"build-2784847793"},"reference-count":41,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Boehringer Ingelheim Hellas (BI) Single Member S.A","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["ARM"],"abstract":"<jats:p>Background: Nintedanib and pirfenidone are two anti-fibrotic agents for diseases within the interstitial lung diseases (ILDs) spectrum. Here, we provide a comprehensive analysis regarding treatment persistence and adherence rates for the Greek territory. Methods: This was a retrospective cohort study of patients initiating anti-fibrotic treatment during the period 2019\u20132023, utilizing data extracted from the National Electronic Prescription Database. Treatment persistence was defined as the duration from the date of the first prescription to the end of follow-up, death, or switching to another agent. Adherence was estimated based on the Medication Possession Ratio (MPR) metric. Results: Overall, 2112 patients were analyzed. The majority were naive, male patients with a diagnosis of idiopathic pulmonary fibrosis (IPF). The overall median treatment persistence was 40.2 months (95% CI: 35.5\u201344.6). Women and treatment-naive patients demonstrated longer median treatment persistence compared to their counterparts, while older patients demonstrated the lowest median persistence rates. Adherence levels remained high across the follow-up period (90%). Diagnosis of IPF and gastrointestinal comorbidities were associated with a higher risk of discontinuation. Conclusions: We have generated novel data concerning the factors that affect patients\u2019 outcomes under anti-fibrotic therapy. These findings may provide helpful insights for the therapeutic management of ILDs.<\/jats:p>","DOI":"10.3390\/arm94010006","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T15:33:16Z","timestamp":1767886396000},"page":"6","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Treatment Adherence and Persistence of Anti-Fibrotic Drugs in Real Life in Greece"],"prefix":"10.3390","volume":"94","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1364-9488","authenticated-orcid":false,"given":"Georgia","family":"Kourlaba","sequence":"first","affiliation":[{"name":"Department of Nursing, University of the Peloponnese, Erythrou Stavrou (Terma), 22100 Tripoli, Greece"},{"name":"Department of Nursing, National and Kapodistrian University of Athens (NKUA), Papadiamantopoulou 123, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stylianos","family":"Ravanidis","sequence":"additional","affiliation":[{"name":"Department of Nursing, University of the Peloponnese, Erythrou Stavrou (Terma), 22100 Tripoli, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garyfallia","family":"Stefanou","sequence":"additional","affiliation":[{"name":"Department of Nursing, University of the Peloponnese, Erythrou Stavrou (Terma), 22100 Tripoli, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4422-1521","authenticated-orcid":false,"given":"Konstantinos","family":"Mathioudakis","sequence":"additional","affiliation":[{"name":"IDIKA SA\u2014e-Government Center for Social Security Services, Lykoyrgou 10, 10551 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anastasios","family":"Tsolakidis","sequence":"additional","affiliation":[{"name":"IDIKA SA\u2014e-Government Center for Social Security Services, Lykoyrgou 10, 10551 Athens, Greece"},{"name":"Department of Archival, Library and Information Studies, University of West Attica, 12243 Egaleo, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitrios","family":"Zografopoulos","sequence":"additional","affiliation":[{"name":"Ministry of Health, Aristotelous 17, 10433 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Althobiani, M.A., Russell, A.M., Jacob, J., Ranjan, Y., Folarin, A.A., Hurst, J.R., and Porter, J.C. (2024). Interstitial lung disease: A review of classification, etiology, epidemiology, clinical diagnosis, pharmacological and non-pharmacological treatment. Front. Med., 11.","DOI":"10.3389\/fmed.2024.1296890"},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Yang, M., Tan, Y., Yang, T., Xu, D., Chen, M., and Chen, L. (2025). Efficacy and safety of antifibrotic drugs for interstitial lung diseases other than IPF: A systematic review, meta-analysis and trial sequential analysis. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0318877"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1056\/NEJMoa1402582","article-title":"A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis","volume":"370","author":"King","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2071","DOI":"10.1056\/NEJMoa1402584","article-title":"Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis","volume":"370","author":"Richeldi","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease","volume":"380","author":"Distler","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1056\/NEJMoa1908681","article-title":"Nintedanib in Progressive Fibrosing Interstitial Lung Diseases","volume":"381","author":"Flaherty","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.arbres.2023.12.002","article-title":"The Impact of Switching to a Second Antifibrotic in Patients with Idiopathic Pulmonary Fibrosis: A Retrospective Multicentre Study from the EMPIRE Registry","volume":"60","author":"Gregor","year":"2024","journal-title":"Arch. Bronconeumol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1753466619872890","DOI":"10.1177\/1753466619872890","article-title":"Medication persistence rates and predictive factors for discontinuation of antifibrotic agents in patients with idiopathic pulmonary fibrosis: A real-world observational study","volume":"13","author":"Oishi","year":"2019","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1177\/08971900211008625","article-title":"Adherence, Persistence, and Effectiveness in Real Life. Multicenter Long-Term Study on the Use of Pirfenidone and Nintedanib in the Treatment of Idiopathic Pulmonary Fibrosis","volume":"35","author":"Santoleri","year":"2022","journal-title":"J. Pharm. Pract."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Kaunisto, J., Salomaa, E.R., Koivisto, M., and Myllarniemi, M. (2023). Overall drug treatment of idiopathic pulmonary fibrosis patients from national registries\u2014A real-world study from Finland. BMC Pulm. Med., 23.","DOI":"10.1186\/s12890-023-02630-1"},{"key":"ref_11","doi-asserted-by":"crossref","unstructured":"Majewski, S., Bialas, A.J., Barczyk, A., Batura-Gabryel, H., Buchczyk, M., Doboszynska, A., Gorska, K., Grabowska-Skudlarz, L., Jagielska-Len, H., and Jarzemska, A. (2023). A Real-World Multicenter Retrospective Observational Study on Polish Experience with Nintedanib Therapy in Patients with Idiopathic Pulmonary Fibrosis: The PolExNIB Study. J. Clin. Med., 12.","DOI":"10.3390\/jcm12144635"},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Majewski, S., Bialas, A.J., Buchczyk, M., Gomolka, P., Gorska, K., Jagielska-Len, H., Jarzemska, A., Jassem, E., Jastrzebski, D., and Kania, A. (2020). A multicentre retrospective observational study on Polish experience of pirfenidone therapy in patients with idiopathic pulmonary fibrosis: The PolExPIR study. BMC Pulm. Med., 20.","DOI":"10.1186\/s12890-020-1162-6"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Boutel, M., Boutou, A., Pitsiou, G., Garyfallos, A., and Dimitroulas, T. (2023). Efficacy and Safety of Nintedanib in Patients with Connective Tissue Disease-Interstitial Lung Disease (CTD-ILD): A Real-World Single Center Experience. Diagnostics, 13.","DOI":"10.3390\/diagnostics13071221"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"00172-2019","DOI":"10.1183\/23120541.00172-2019","article-title":"Efficacy and safety of nintedanib in a Greek multicentre idiopathic pulmonary fibrosis registry: A retrospective, observational, cohort study","volume":"6","author":"Antoniou","year":"2020","journal-title":"ERJ Open Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.pupt.2018.01.006","article-title":"Safety and efficacy of nintedanib in idiopathic pulmonary fibrosis: A real-life observational study in Greece","volume":"49","author":"Tzouvelekis","year":"2018","journal-title":"Pulm. Pharmacol. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Tzouvelekis, A., Karampitsakos, T., Ntolios, P., Tzilas, V., Bouros, E., Markozannes, E., Malliou, I., Anagnostopoulos, A., Granitsas, A., and Steiropoulos, P. (2017). Longitudinal \u201cReal-World\u201d Outcomes of Pirfenidone in Idiopathic Pulmonary Fibrosis in Greece. Front. Med., 4.","DOI":"10.3389\/fmed.2017.00213"},{"key":"ref_17","first-page":"264","article-title":"Medication adherence: Measurement methods and approaches","volume":"125","author":"Schnorrerova","year":"2024","journal-title":"Bratisl. Lek. Listy"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.2147\/PPA.S136890","article-title":"An upper and lower bound of the Medication Possession Ratio","volume":"11","author":"Sperber","year":"2017","journal-title":"Patient Prefer. Adher."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Leuschner, G., Klotsche, J., Kreuter, M., Prasse, A., Wirtz, H., Pittrow, D., Frankenberger, M., Behr, J., Kneidinger, N., and INSIGHTS-IPF Registry Group (2020). Idiopathic Pulmonary Fibrosis in Elderly Patients: Analysis of the INSIGHTS-IPF Observational Study. Front. Med., 7.","DOI":"10.3389\/fmed.2020.601279"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/j.resinv.2023.04.007","article-title":"Elderly idiopathic pulmonary fibrosis patients remain on therapy despite higher incidence of adverse events and dose reductions","volume":"61","author":"Cilli","year":"2023","journal-title":"Respir. Investig."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Majewski, S., Gorska, K., Lewandowska, K.B., Martusewicz-Boros, M.M., Sobiecka, M., and Piotrowski, W.J. (2025). Real-world treatment persistence and predictive factors for discontinuation of antifibrotic therapies in patients with idiopathic pulmonary fibrosis: A post-hoc analysis of two multicenter observational cohort studies in Poland. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1586197"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Margaritopoulos, G.A., Trachalaki, A., Wells, A.U., Vasarmidi, E., Bibaki, E., Papastratigakis, G., Detorakis, S., Tzanakis, N., and Antoniou, K.M. (2018). Pirfenidone improves survival in IPF: Results from a real-life study. BMC Pulm. Med., 18.","DOI":"10.1186\/s12890-018-0736-z"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"e001687","DOI":"10.1136\/bmjresp-2023-001687","article-title":"Antifibrotic treatment adherence, efficacy and outcomes for patients with idiopathic pulmonary fibrosis in Spain: A real-world evidence study","volume":"11","year":"2024","journal-title":"BMJ Open Respir. Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1136\/thoraxjnl-2019-213968","article-title":"Patient gender bias on the diagnosis of idiopathic pulmonary fibrosis","volume":"75","author":"Assayag","year":"2020","journal-title":"Thorax"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.rmed.2009.11.019","article-title":"Gender influences Health-Related Quality of Life in IPF","volume":"104","author":"Han","year":"2010","journal-title":"Respir. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1183\/09031936.00165207","article-title":"Sex differences in physiological progression of idiopathic pulmonary fibrosis","volume":"31","author":"Han","year":"2008","journal-title":"Eur. Respir. J."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Tondo, P., Scioscia, G., De Pace, C.C., Murgolo, F., Maci, F., Stella, G.M., Pescatore, D., Foschino Barbaro, M.P., and Lacedonia, D. (2025). Gender Differences Are a Leading Factor in 5-Year Survival of Patients with Idiopathic Pulmonary Fibrosis over Antifibrotic Therapy Reduction. Life, 15.","DOI":"10.3390\/life15010106"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Sese, L., Nunes, H., Cottin, V., Israel-Biet, D., Crestani, B., Guillot-Dudoret, S., Cadranel, J., Wallaert, B., Tazi, A., and Maitre, B. (2021). Gender Differences in Idiopathic Pulmonary Fibrosis: Are Men and Women Equal?. Front. Med., 8.","DOI":"10.3389\/fmed.2021.713698"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1136\/jech-2019-213435","article-title":"Do men avoid seeking medical advice? A register-based analysis of gender-specific changes in primary healthcare use after first hospitalisation at ages 60+ in Denmark","volume":"74","author":"Hohn","year":"2020","journal-title":"J. Epidemiol. Community Health"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Suzuki, Y., Mori, K., Aono, Y., Kono, M., Hasegawa, H., Yokomura, K., Naoi, H., Hozumi, H., Karayama, M., and Furuhashi, K. (2021). Switching antifibrotics in patients with idiopathic pulmonary fibrosis: A multi-center retrospective cohort study. BMC Pulm. Med., 21.","DOI":"10.1186\/s12890-021-01587-3"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"180076","DOI":"10.1183\/16000617.0076-2018","article-title":"Presentation, diagnosis and clinical course of the spectrum of progressive-fibrosing interstitial lung diseases","volume":"27","author":"Cottin","year":"2018","journal-title":"Eur. Respir. Rev."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1753466620910092","DOI":"10.1177\/1753466620910092","article-title":"Comorbidity in idiopathic pulmonary fibrosis\u2014What can biomarkers tell us?","volume":"14","author":"Alfaro","year":"2020","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"328","DOI":"10.24171\/j.phrp.2022.0168","article-title":"Effects of medication adherence interventions for older adults with chronic illnesses: A systematic review and meta-analysis","volume":"13","author":"Jeon","year":"2022","journal-title":"Osong Public Health Res. Perspect."},{"key":"ref_34","first-page":"2300","article-title":"The association between social support and medication adherence in patients with hypertension: A systematic review","volume":"19","author":"Shahin","year":"2021","journal-title":"Pharm. Pract."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Horvat, M., Erzen, I., and Vrbnjak, D. (2024). Barriers and Facilitators to Medication Adherence among the Vulnerable Elderly: A Focus Group Study. Healthcare, 12.","DOI":"10.3390\/healthcare12171723"},{"key":"ref_36","first-page":"196","article-title":"Regional Distribution Disparities of Healthcare Resources in Greece","volume":"6","author":"Gogos","year":"2022","journal-title":"Eur. Mod. Stud. J."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Xu, J., Zhao, M., Vrosgou, A., Yu, N.C.W., Liu, C., Zhang, H., Ding, C., Roth, N.W., Pan, Y., and Liu, L. (2021). Barriers to medication adherence in a rural-urban dual economy: A multi-stakeholder qualitative study. BMC Health Serv. Res., 21.","DOI":"10.1186\/s12913-021-06789-3"},{"key":"ref_38","first-page":"100041","article-title":"Exploring Racial and Ethnic Disparities in Medication Adherence Among Medicare Comprehensive Medication Review Recipients","volume":"3","author":"Dong","year":"2021","journal-title":"Explor. Res. Clin. Soc. Pharm."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Asiri, R., Todd, A., Robinson-Barella, A., and Husband, A. (2023). Ethnic disparities in medication adherence? A systematic review examining the association between ethnicity and antidiabetic medication adherence. PLoS ONE, 18.","DOI":"10.1371\/journal.pone.0271650"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Hershko, T., Freund, O., Schneer, S., Segel, M.J., Wand, O., Bar-Shai, A., Shitrit, D., Levy, L., Adir, Y., and Unterman, A. (2025). Interstitial Lung Diseases in Israel: Large Variability in Close Geographic Proximity. Diagnostics, 15.","DOI":"10.3390\/diagnostics15212780"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"240171","DOI":"10.1183\/20734735.0171-2024","article-title":"Systemic autoimmune rheumatic diseases-associated interstitial lung disease: A pulmonologist\u2019s perspective","volume":"21","author":"Boyle","year":"2025","journal-title":"Breathe"}],"container-title":["Advances in Respiratory Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2543-6031\/94\/1\/6\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,15]],"date-time":"2026-01-15T05:15:18Z","timestamp":1768454118000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2543-6031\/94\/1\/6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["arm94010006"],"URL":"https:\/\/doi.org\/10.3390\/arm94010006","relation":{},"ISSN":["2543-6031"],"issn-type":[{"value":"2543-6031","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]}}}